Trumbull, Conn., Oct. 10, 2022 (GLOBE NEWSWIRE) — ZetrOZ Systems, creator and manufacturer of the sam® product line of wearable ultrasound devices, is continuing to expand its clinical education program on the impact of continuous acoustic medicine on soft tissue Healing benefits, use of pain relief treatments and access to health insurance for pain relief devices.
Sustained Acoustic Medicine (sam®) is the only at-home bioregenerative medical device approved by the U.S. Food and Drug Administration for the treatment of specific medical indications, most commonly chronic joint pain in the shoulders, knees, and elbows, and overtreatment Use damage. Over 50 clinical and scientific studies support its effectiveness in healing injuries, restoring function and returning patients to work and daily activities.
“Our sam® technology touches thousands of lives every day, and we hope to continue to educate more health care providers to bring this innovative intervention to Americans who can benefit from this treatment ,” said Dr. George Lewis, founder and CEO of ZetrOZ Systems. “This technology provides results without the need for opioids or other drugs, while simultaneously treating and curing patients 40 percent faster than standard methods.”
Clinical education at sam® is directed by a Ph.D. Rod Walters and Dr. Rajiv Malipurdi. Walters is a nationally recognized leader in athletic training, with decades of experience at major universities and consulting for clients including the NFL, Big 12 and Cirque du Soleil. He was inducted into the National Athletic Trainers Association Hall of Fame in 2005.
PhD. Mallipudi, MD, MHS, is a board-certified internal medicine resident and clinical assistant professor at Yale University School of Medicine in New Haven, Connecticut. He is an active healthcare quality improvement clinical researcher with projects investigating ways to shorten hospital stays and improve patient outcomes.
Walters and Mallipudi’s shared goal is to educate physicians, physical therapists, and athletic trainers about the benefits and use of the sam® device, with a view to reducing the need for surgery and pain medication, and improving the likelihood of patients returning to work, exercise, and recovery. normal daily activities. By providing clinical training resources, including online videos, medical professionals can now access information on best practices for drug-free and non-invasive treatment of patient injuries.
Adherence to the sam® regimen throughout the repair phase provides necessary and safe interventions to ensure patients avoid chronic, recurrent injury. Recommended practices are detailed in educational materials, including:
- sam® therapy can be applied with one or two ultrasound stimulators.
- The sam® device should be used at least four times a week.
- Treatment should be applied gradually to assess the patient’s response to treatment, from the initial one hour of treatment to a maximum of four hours per treatment.
- For acute conditions, the duration of treatment can vary from 4 to 8 weeks.
- For chronic conditions, the duration of treatment is 2 to 12 weeks.
Clinical Education Instructs Physician sam® can be used as a stand-alone treatment or in addition to other treatments to stimulate soft tissue repair, and it has value as a treatment option that does not require surgery or pain medication.
sam® treatment is also a cost-effective treatment option.For example, a 2020 study on knee osteoarthritis was published in Journal of Plastic Surgery and Researchsam® was found to provide greater improvement over standard care options in functional effectiveness per dollar of care.
ZetrOZ Systems continues to provide education on sam® technology, most recently participating in the annual PHATS (Society of Professional Hockey Sports Coaches) SPHEM (Society of Professional Hockey Equipment Managers) 2022 conference in June. The findings suggest that sam® is a non-invasive, non-narcotic pain substitute and the ease of use of the device allows athletes to resume normal activities after treatment.
To learn more, visit zetrozsystems.com.
About the ZetrOZ System
ZetrOZ Systems leads therapeutic innovation in sports medicine, developing wearable bioelectronics to provide continuous acoustic medicine (sam®). Federally researched and funded and built on proprietary medical technology with +46 patents, ZetrOZ is the exclusive manufacturer and developer of sam®, a line of products designed to treat acute and chronic musculoskeletal disorders. To learn more, visit zetrozsystems.com.
This content was distributed through Newswire.com’s press release distribution service.
Featured image of the ZetrOZ system